When a Negative Cannabis Urine Screen Needs a Specimen-Validity Review
A negative cannabis immunoassay can reflect analytical interference rather than absence of the target metabolite. A laboratory study of benzalkonium chloride illustrates that vulnerability and a way to investigate it. It does not justify assuming that every negative sample was deliberately altered.
What chemical was the test trying to detect?
The lateral-flow urine tests examined in this study targeted THC-COOH, a cannabis metabolite. That is different from measuring parent THC in blood or assessing a person’s current function.
Finn and colleagues investigated whether benzalkonium chloride, a surfactant, could interfere with the immunoassay response. Experiments showed that affected samples could change from a positive to a negative screening result despite the metabolite being present. The proposed mechanism involved reduced availability of the target for antibody detection.
What did the blinded experiment show?
The researchers developed a screening approach using standard addition to help distinguish unaffected negatives from interference-related negatives. In a blinded set of 45 samples—15 true positives, 15 true negatives, and 15 interference-related false negatives—the method identified the adulterated samples.
This is a controlled analytical finding, not a population estimate of how often urine samples are altered. The study examined a limited selection of kits and constructed sample conditions. Excellent performance in that set does not establish zero error across all donors, products, instruments, or interferents.
Why a negative result alone is insufficient
A negative result can also occur when the target is genuinely absent or below a test’s cutoff. The interference mechanism demonstrated here cannot establish which explanation applies to a particular person’s specimen without additional evidence.
Likewise, an unexpected result does not by itself establish intent. Sample collection records, validity testing, assay controls, and a suitable independent analytical method should inform the interpretation.
Practical questions for evidence review
Identify the test manufacturer, target analyte, cutoff, and specimen-validity procedures. Ask whether an interference was measured or merely proposed and whether further testing resolved the discrepancy.
The study concerns reliability of metabolite detection in urine. Neither its positive results nor its false negatives establish impairment, the dose consumed, or a precise last-use time. Those are separate questions requiring their own evidence.
For related context, see our discussion of why urine and blood drug results are not interchangeable.
Primary research
Éabha Finn; Jennifer Huffman; Kristen J. Skogerboe. Behind the Mask: Detection and Characterization of Benzalkonium Chloride Adulteration in Immunoassay-Based Urine Drug Testing for Tetrahydrocannabinol (THC). ACS Omega (2026). DOI: 10.1021/acsomega.6c03171.
